Europe Lidocaine Market

Market Overview

The Europe Lidocaine Market size is expected to reach a valuation of USD 906.81 million by 2030, increasing at a rate of 8.80 % CAGR during the forecast period (2022–2030).

Lidocaine is a local anaesthetic made from an aminoethyl amide derived from xylidine. It has a longer-lasting, broader, and quicker action than other anaesthetics like procaine. The number of surgical procedures executed around the world, such as dental procedures, aesthetic surgery, and plastic surgeries, is expected to increase. Some of the main drivers driving the market growth are the rise in chronic and acute pain disorders around the world, as well as the numerous benefits associated with lidocaine hydrochloride. A notable trend in the market is a significant increase in the requirement for postoperative pain management treatments, which follows an increase in the number of surgical procedures. As a result of this tendency, the demand for lidocaine hydrochloride is expected to continue to climb. According to the study "Postoperative Pain Control," over 75% of people who have surgery experience acute postoperative pain, which is usually moderate to severe in severity, which helps them grow faster.

During the projection period, Europe is predicted to be the second-largest lidocaine market, owing to an increase in the number of significant patients, operations, and the utilisation of lidocaine injections as local anaesthetics during surgeries.

Market Dynamics

Europe Lidocaine Market Drivers

• Mounting healthcare and R & D Investments: In 2019, the pharmaceutical sector of Europe spent billions on research and development. These costs were incurred for a number of operations, including the discovery and testing of novel medications, the development of incremental advancements such as product expansions, and clinical testing for safety monitoring and marketing. After adjusting for inflation, that sum is around ten times what the industry spent every year in the 1980s. The percentage of sales that pharmaceutical companies dedicate to R&D has increased as well: in 2019, pharmaceutical companies spent around one-quarter of their revenues on R&D expenses, about twice as much as they did in 2000 and this is expected to drive the market of the Lidocaine towards growth in

• Increase in the number of Surgeries: The World Health Organization estimates that the region's senior population would nearly triple by 2050 compared to 2020. An increment in the number of surgeries executed as a result of an ageing population that is more susceptible to chronic diseases such as cancer, cardiovascular disorders, neurological disorders, respiratory misalignment, and orthopaedic, and spinal difficulties, among other things, will lead to an increase in Lidocaine demand in the European

Europe Lidocaine Market Restraints

• Associated Health Risks: Lidocaine can produce numbness in the lips and throat, making it difficult to swallow and potentially resulting in choking. If a considerable amount is swallowed, enough can enter the bloodstream to injure vital organs, particularly the brain and heart. Symptoms might range from modest weariness and headaches to confusion, convulsions, coma, and cardiac arrest. Another serious side effect of lidocaine is a disease known as methemoglobinemia. The ability of red blood cell iron to deliver oxygen to tissues may be affected by lidocaine. Methemoglobinemia is a blood ailment in which the iron in the blood is of a different kind. Even with routine lidocaine use, methemoglobinemia can occur, especially in children, and these concerns could limit market growth in Europe.

Europe Lidocaine Market Opportunities

• Geriatric Population Growth: People in the region and around the world are living longer. Nowadays, most people may expect to live into their sixties and beyond. Every country on the planet is experiencing population growth and an increase in the number of old individuals. Adults of age 60 and up will have doubled in number by 2050. (2.1 billion). The number of people of age 80 and over is expected to triple between 2020 and 2050, resulting in a rise in the number of procedures and treatments, giving attractive potential for Lidocaine's primary European market participants.

Regional Analysis

By 2030, the Europe Lidocaine Market is estimated to be worth USD 906.81 million, growing at an annual rate of 8.80% from 2022 to 2030. Due to an increase in the number of significant patients, operations, and the use of lidocaine injections as local anaesthetics during surgeries, Europe is expected to be the second-largest lidocaine market throughout the projected period. Due to the rising frequency of diabetic neuropathy, Europe is likely to rise significantly in the next years. According to the National Centre for Biotechnology Information (NCBI), the prevalence of Painful Diabetic Peripheral Neuropathy (PDPN) among patients with diabetes ranges from 5.8% to 34% throughout Europe. The reported prevalence of PDPN in diabetes mellitus patients in Europe ranged from 0.7% to 34% in all research reviewed. Furthermore, throughout the projected period, the market in Europe is expected to rise due to an increase in surgical operations and easy access to products across the region.

Due to rising demand for lidocaine formulations, operations, and higher investments in the healthcare industry, the United Kingdom Lidocaine Market is likely to be the largest in Europe. In the UK, over 28 thousand cosmetic operations were performed in 2019. In 2015, about 52 thousand treatments were conducted in the field of cosmetic surgery. Between 2006 and 2016, these figures climbed nearly fivefold. These figures are expected to rise over time, resulting in higher market sales revenues.

During the analysis period, the regional market in Germany's Lidocaine Market has shown incredible market expansion, rising at a considerably excellent CAGR. The increasing frequency of regional procedures, awareness of lidocaine ointment as a local anaesthetic agent, and a huge patient population are all contributing to market expansion. In 2018, the German market accounted for roughly 26.9% of the European lidocaine market. The number of cosmetic treatments performed in Germany has been estimated to be over 923,000. Other European countries are expected to expand at a robust and consistent pace as well.

Segmental Analysis

According to the formulation, the section is divided into injections, creams, ointments, gels, and others. Lidocaine hydrochloride is available in a number of different forms, including a 2% viscous solution, a 2% gel, a 4% solution, and a 10% topical spray. Lidocaine base is available in 5%, 2.5%, and 10% concentrations in solutions and ointments, as well as a 10% aerosol spray. Furthermore, the ointments category is likely to grow at the quickest rate during the forecast period. This is due to the growing use of lidocaine ointments as cosmetic surgery products.

Depending on the application, the section is divided into dental, cardiac arrhythmia, epilepsy, aesthetic surgery, general surgery, and others. The dentistry industry is predicted to have the greatest market share in 2020. The demand for injectable lidocaine hydrochloride solutions in dental surgical procedures is driving its dominance. This, together with a rise in the number of dental problems and chronic and acute pain associated with dental operations, is expected to move the market ahead. Oral problems will affect about 3.5 billion individuals by 2020, according to the World Health Organization.

Based on distribution channels, the market is divided into hospital outlets, retail pharmacies, and others. The hospital outlets segment will account for the majority of the lidocaine market in the region by 2020. This is mostly due to better infrastructure and facilities, as well as a growth in the incidence of dental, aesthetic, and general operations, higher awareness of illness diagnosis and treatment, and an increase in the number of patients globally.

During the assessment period, the market expansion will be aided by the establishment of hospital pharmacies in cardiology, neurology, and other illnesses in both developed and developing countries, as well as an increase in the number of hospitals and appropriate reimbursement scenarios.

Recent Developments

• Premier Inc. teamed with Amphastar Pharmaceuticals, to deliver phytonadione injection and emergency, pre-filled syringes containing calcium chloride, epinephrine, sodium bicarbonate, atropine sulphate, dextrose, and lidocaine to healthcare practitioners through its ProvideGx programme.